Therapy News and Research

RSS

Patients rely on the Internet for prescribed treatments and disease management

Today's consumers are more and more likely to turn to the Internet for medical and drug information. About.com's recent Health Site Intercept Study finds that, among Web-using patients who receive a diagnosis, only 35% rely completely on a doctor for decisions about prescriptions and treatment.

18 Sep 2009

NIDDK awards $1.2 million grant to Bolder BioTechnology for long-acting EPO analog program

Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

18 Sep 2009

FDA approves Valturna tablets for treating high blood pressure

The US Food and Drug Administration (FDA) has approved Valturna((R)) (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.

18 Sep 2009

Preventive treatment extension after kidney transplantation reduces the risk of CMV disease

For kidney transplant recipients, infection with a virus called cytomegalovirus (CMV) may lead to devastating complications. New research suggests that extending the period of preventive treatment after kidney transplantation can reduce the risk of CMV disease, according to an upcoming report in the Journal of the American Society of Nephrology (JASN).

18 Sep 2009

Calypso Medical raises funds for commercial expansion

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced the completion of a $50 million round of venture capital financing, led by Skyline Ventures and Frazier Healthcare Ventures.

18 Sep 2009

Deterioration in brain function following breast cancer therapy has negative effects on quality of life

One of the most problematic side effects of cancer treatment, chemobrain - a range of symptoms including memory loss, inability to concentrate, difficulty thinking and other subtle cognitive changes following chemotherapy - seriously diminishes women's quality of life and daily functioning.

18 Sep 2009

Lantheus commences Phase 1 study evaluating novel LMI1195 heart failure imaging agent

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the initiation of a Phase 1 clinical study to assess the safety, dosimetry and tolerability of LMI1195, a novel F-18 small molecule tracer for imaging cardiac neuronal function, in healthy subjects, undergoing positron emission tomography (PET) imaging.

17 Sep 2009

Nimotuzumab drug approved for Mexican distribution

YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico.

17 Sep 2009

Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment

Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily injection form of exenatide.

17 Sep 2009

Educational initiative proves successful in identifying and diagnosing fibromyalgia

According to The Johns Hopkins University School of Medicine, the Fibromyalgia Circle of Care Initiative has achieved dramatic success in heightening awareness, diagnosis and best practice treatment of fibromyalgia – a complex and chronic pain disorder that plagues an estimated 10 million Americans.

17 Sep 2009

Deterioration in brain function following breast cancer therapy affects quality of life: Study

17 Sep 2009

Pervasis Therapeutics raises funds to support clinical development programs

Pervasis Therapeutics, Inc. today announced that it completed the initial closing of a $17 million third round of financing. The proceeds will be used primarily to support the company's ongoing clinical development programs, including PVS-10200, a biologically active therapy designed to reestablish healthy vasculature following common interventions to treat peripheral arterial disease (PAD) and potentially other conditions.

17 Sep 2009

Northeast Pennsylvania healthcare facilities collaborate to eliminate laboratory errors

Healthcare facilities in northeast Pennsylvania have come together to reduce and eliminate laboratory errors due to specimen mislabeling. Pocono Medical Center helped to spearhead the effort when they noticed they were reporting a large number of mislabeled lab specimens at their facility that coincided with data delivered in a presentation by the Pennsylvania Patient Safety Authority.

17 Sep 2009

Advanced radiosurgery technology utilized by Cyberknife for effective cancer treatment

Cyberknife of Long Island has become the first cancer center in New York to treat tumors with the most advanced radiosurgery technology available to date.

17 Sep 2009

NCPA happy with Baucus' proposals for community pharmacies

The National Community Pharmacists Association (NCPA) commended Senate Finance Committee Chair Max Baucus (D-MT) for including several critical provisions to help community pharmacies better serve patients in the “America’s Healthy Future Act” proposed today.

17 Sep 2009

Workshop to educate women on urinary incontinence

UCSF and the National Association For Continence (NAFC) are holding a public workshop on October 3 to help women understand how they can control and treat incontinence.

17 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

Charley's Fund and the Nash Avery Foundation to support investigation of Galapagos' SARM candidate drug

Galapagos NV (Euronext: GLPG), Charley's Fund Inc. and the Nash Avery Foundation announced today that they will collaborate to investigate the potential effectiveness of Galapagos' SARM candidate drug, G100192, in treating Duchenne muscular dystrophy. G100192 is an orally-available small molecule therapeutic, which has demonstrated successful Proof of Concept in pre-clinical studies for cachexia (the loss of weight and muscle mass).

17 Sep 2009

Mechanism of action of the anti-cancer drug GMX1778 identified

Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published identifying the mechanism of action of the anti-cancer drug GMX1778. Co-authored by scientists at Gemin X Pharmaceuticals and Metabolon, the paper “The Small Molecule GMX1778 is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in NAPRT1-Deficient Tumors” appears online ahead of print in Molecular and Cellular Biology.

17 Sep 2009

Quest PharmaTech reports second quarter fiscal 2009 results

Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced fiscal second quarter results for the period ended July 31, 2009.

17 Sep 2009

Therapy News and Research

Patients rely on the Internet for prescribed treatments and disease management

NIDDK awards $1.2 million grant to Bolder BioTechnology for long-acting EPO analog program

FDA approves Valturna tablets for treating high blood pressure

Preventive treatment extension after kidney transplantation reduces the risk of CMV disease

Calypso Medical raises funds for commercial expansion

Deterioration in brain function following breast cancer therapy has negative effects on quality of life

Lantheus commences Phase 1 study evaluating novel LMI1195 heart failure imaging agent

Nimotuzumab drug approved for Mexican distribution

Intarcia's ITCA 650 phase 2 study in type 2 diabetes begins patient enrollment

Educational initiative proves successful in identifying and diagnosing fibromyalgia

Deterioration in brain function following breast cancer therapy affects quality of life: Study

Pervasis Therapeutics raises funds to support clinical development programs

Northeast Pennsylvania healthcare facilities collaborate to eliminate laboratory errors

Advanced radiosurgery technology utilized by Cyberknife for effective cancer treatment

NCPA happy with Baucus' proposals for community pharmacies

Workshop to educate women on urinary incontinence

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Charley's Fund and the Nash Avery Foundation to support investigation of Galapagos' SARM candidate drug

Mechanism of action of the anti-cancer drug GMX1778 identified

Quest PharmaTech reports second quarter fiscal 2009 results

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News